Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40

• Richard G. Langley, MD,
• Chiranjeev Sanyal, PhD,
• Aaron Situ, MSc,
• Sarah Alulis, MSc,
• Fareen Hassan, MSc,
• Steve Peterson, MPH,
• Rachel E. Teneralli, PhD,
• Jennifer Lee, MBA,
• Barkha P. Patel, PhD,
• Tim Disher, PhD

Affiliations

Richard G. Langley, MD

Division of Clinical Dermatology & Cutaneous Science, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

Chiranjeev Sanyal, PhD

Department of Community Health and Epidemiology, College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, Canada; CRG-EVERSANA, Value and Evidence Services, Burlington, Ontario, Canada

Aaron Situ, MSc

CRG-EVERSANA, Value and Evidence Services, Burlington, Ontario, Canada; Tigermed BDM, Somerset, New Jersey

Sarah Alulis, MSc

Janssen-Cilag A/S, Birkerød, Denmark

Fareen Hassan, MSc

Janssen-Cilag Ltd, High Wycombe, United Kingdom

Steve Peterson, MPH

Janssen Immunology Global Commercial Strategy Organization, Horsham, Pennsylvania

Rachel E. Teneralli, PhD

Janssen Immunology Global Commercial Strategy Organization, Horsham, Pennsylvania

Jennifer Lee, MBA

Janssen-Cilag A/S, Birkerød, Denmark

Barkha P. Patel, PhD

CRG-EVERSANA, Value and Evidence Services, Burlington, Ontario, Canada

Tim Disher, PhD

CRG-EVERSANA, Value and Evidence Services, Burlington, Ontario, Canada; Correspondence to: Tim Disher, RN, PhD, EVERSANA, 3228 S Service Rd, Burlington, ON, L7N 3H8, Canada